公开(公告)号：US20230279090A1

公开(公告)日：2023-09-07

申请号：US18301187

申请日：2023-04-14

申请人： Genentech, Inc. ,  HOFFMANN-LA ROCHE INC.

发明人： Stefan Dengl ,  Rami Hannoush ,  Simon Theodor Hansen ,  Peter Michael Huelsmann ,  Robert Franklin Kelley ,  Hubert Kettenberger ,  Shrenik Chetan Mehta ,  Devin Brent Tesar

IPC分类号： C07K16/22 ,  C07K14/705 ,  A61P27/02

CPC分类号： C07K16/22 ,  A61P27/02 ,  C07K14/70578 ,  C07K14/70585

摘要： A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.